Regeneron COVID-19 antibody therapy cuts death risk in hospitalized patients lacking immune response

Regeneron’s COVID-19 therapy was found to reduce the risk of death in hospitalized patients who had not mounted their own immune response to the virus by up to 20%, the company said Wednesday